Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 0.71 |
| ▸ | MMP9 | P14780 | 19/20 | 0.71 |
| ▸ | MMP1 | P03956 | 9/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7680259 | 0.89 | MMP2 (0.58) | MMP2MMP9MMP1 | |
| SCHEMBL7673474 | 0.83 | MMP2 (1.00) | MMP2MMP9MMP1 | |
| SCHEMBL7671031 | 0.83 | MMP2 (1.00) | MMP2MMP9MMP1 | |
| SCHEMBL8000598 | 0.83 | MMP2 (1.00) | MMP2MMP9MMP1 | |
| SCHEMBL7677334 | 0.83 | MMP2 (1.00) | MMP2MMP9MMP1 | |
| SCHEMBL7990342 | 0.82 | MMP2 (0.82) | MMP2MMP9MMP1 | |
| SCHEMBL7670647 | 0.81 | MMP2 (0.83) | MMP2MMP9MMP1 | |
| SCHEMBL7673693 | 0.81 | MMP2 (0.83) | MMP2MMP9MMP1 | |
| SCHEMBL8002008 | 0.80 | MMP2 (1.00) | MMP2MMP9MMP1 | |
| SCHEMBL7990013 | 0.80 | MMP2 (1.00) | MMP2MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | claimed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | MMP2 4/4885MMP9 2/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.